APA (7th ed.) Citation

Mazri, M. S. (2023). Effectiveness of luseogliflozin over conventional therapy on liver fibrosis, disease activity and metabolic attributes in patients with metabolic associated fatty liver disease and type ii diabetes mellitus: An open-label randomized controlled trial.

Chicago Style (17th ed.) Citation

Mazri, Mohamad Syamil. Effectiveness of Luseogliflozin over Conventional Therapy on Liver Fibrosis, Disease Activity and Metabolic Attributes in Patients with Metabolic Associated Fatty Liver Disease and Type Ii Diabetes Mellitus: An Open-label Randomized Controlled Trial. 2023.

MLA (9th ed.) Citation

Mazri, Mohamad Syamil. Effectiveness of Luseogliflozin over Conventional Therapy on Liver Fibrosis, Disease Activity and Metabolic Attributes in Patients with Metabolic Associated Fatty Liver Disease and Type Ii Diabetes Mellitus: An Open-label Randomized Controlled Trial. 2023.